Zhang Hongfu, Li Jing, Wan Xin, Liu Zhuoyi
Department of Neurosurgery, Henan Provincial People's Hospital, Zhengzhou University People's Hospital; Henan University People's Hospital, Zhengzhou, 450003, Henan, China.
Department of Rehabilitation, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Discov Oncol. 2024 Aug 31;15(1):394. doi: 10.1007/s12672-024-01263-y.
Comprehensive investigations of the prognosis factors and treatment strategies with adjustment of competing causes of death for patients with malignant meningioma (MM) is still lacking.
The surveillance, Epidemiology, and End Results (SEER) database were used to include adult patients with this rare disease between 2004 and 2018. The probability of MM-caused mortality (MMCM) and non-MM-caused mortality (non-MMCM) were presented by cumulative incidence function curves. Then, the association between variates with non-MMCM was evaluated by the cox proportional hazard model, and the prognostic factors of MMCM were identified by Fine-Gray competing risk regression model. Furthermore, a nomogram was developed to predict the 1-year, 2-year, and 5-year MMCM and the performance was tested by a time-dependent area under the receiver operating characteristic (ROC) curve and calibration.
577 patients were included, with a median age of 62 (18-100) years old and a median overall survival time of 36 (0-176) months. The percentage of non-MMCM was 15.4% (n = 89) in the entire population and 21.7% (n = 54) in elderly patients. The multivariable Cox proportional hazard regression model revealed that older age and other tumor(s) before or after MM had an independently significant association with higher non-MMCM. After adjustment of competing causes of death, the multivariable Fine-gray regression model identified age group ≥ 65 year, tumor size > 5.3 cm, recurrent MM, and histologic type 9530/3 (Meningioma, malignant) had an independently significant association with higher MMCM. Compared with gross total (GTR) of tumor, subtotal resection of tumor (HR 1.66, 95%CI 1.08-2.56, P = 0.02), partial resection of lobe (HR 2.26, 95%CI 1.32-3.87, P = 0.003), and gross total resection of lobe (HR 1.69, 95%CI 1.12-2.51, P = 0.01) had an independently significant association with higher MMCM.
The competing risk nomogram including age group, tumor size, initial status, histologic type, and extent of resection is discriminative and clinically useful. This study emphasized the importance of the GTR of tumor in the treatment of MM patients, which had a significantly lower incidence of MMCM compared with biopsy, STR of tumor, partial resection of lobe, and GTR of lobe.
目前仍缺乏对恶性脑膜瘤(MM)患者的预后因素和治疗策略进行全面调查,并对死亡的竞争原因进行调整。
使用监测、流行病学和最终结果(SEER)数据库纳入2004年至2018年间患有这种罕见疾病的成年患者。MM导致的死亡率(MMCM)和非MM导致的死亡率(非MMCM)通过累积发病率函数曲线呈现。然后,通过Cox比例风险模型评估变量与非MMCM之间的关联,并通过Fine-Gray竞争风险回归模型确定MMCM的预后因素。此外,还开发了一种列线图来预测1年、2年和5年的MMCM,并通过受试者操作特征(ROC)曲线下的时间依赖性面积和校准来测试其性能。
共纳入577例患者,中位年龄为62岁(18 - 100岁),中位总生存时间为36个月(0 - 176个月)。在整个人口中,非MMCM的比例为15.4%(n = 89),老年患者中为21.7%(n = 54)。多变量Cox比例风险回归模型显示,年龄较大以及MM之前或之后患有其他肿瘤与较高的非MMCM独立显著相关。在调整死亡的竞争原因后,多变量Fine-gray回归模型确定年龄≥65岁、肿瘤大小>5.3 cm、复发性MM和组织学类型9530/3(恶性脑膜瘤)与较高的MMCM独立显著相关。与肿瘤全切除(GTR)相比,肿瘤次全切除(HR 1.66,95%CI 1.08 - 2.56,P = 0.02)、叶部分切除(HR 2.26,95%CI 1.32 - 3.87,P = 0.003)和叶全切除(HR 1.69,95%CI 1.12 - 2.51,P = 0.01)与较高的MMCM独立显著相关。
包括年龄组、肿瘤大小、初始状态、组织学类型和切除范围的竞争风险列线图具有鉴别力且临床有用。本研究强调了肿瘤GTR在MM患者治疗中的重要性,与活检、肿瘤次全切除、叶部分切除和叶全切除相比,其MMCM发生率显著较低。